Clinical TrialApr 27, 2026, 06:51 AM
ETON Doses First Patient in ET-700 Pilot Study for Wilson Disease
AI Summary
Eton Pharmaceuticals, Inc. announced the dosing of the first patient in a pilot clinical study for ET-700, its proprietary extended-release zinc acetate formulation for Wilson disease. This study aims to assess the efficacy of a simpler dosing regimen using 64Cu PET imaging to reduce intestinal copper absorption. Topline results are anticipated in the second half of 2026, with a pivotal study planned for early 2027 if the pilot is successful. The company believes ET-700 could achieve over $100 million in peak annual sales in the U.S.
Key Highlights
- ETON dosed the first patient in a pilot clinical study for ET-700, an extended-release zinc acetate for Wilson disease.
- Topline study results for ET-700 are expected in the second half of 2026.
- A pivotal clinical study for ET-700 is planned for early 2027, if pilot results are positive.
- ET-700 has the potential to exceed $100 million in peak annual sales in the United States.
- The study is a double-blinded, placebo-controlled trial with 36 healthy volunteers.
- It compares GALZIN 50mg (3x daily) to ET-700 75mg (2x daily) plus placebo.
- The study uses 64Cu PET imaging to assess intestinal copper absorption over four weeks.
Price Impact
More from ETON